| Melissa I Costner, MD | |
|
17051 Dallas Pkwy Ste 350, Addison, TX 75001-7107 | |
| (214) 702-0029 | |
| (214) 382-3453 |
| Full Name | Melissa I Costner |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 31 Years |
| Location | 17051 Dallas Pkwy Ste 350, Addison, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265491302 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | J5980 (Texas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dallas Dermatology Partners, Pllc | 8022449446 | 5 |
News Archive
An important new study has revealed the clearest picture yet of precisely how much measurement variation influences gene expression profiles of breast cancer.
YM BioSciences Inc., announced that the FDA has advised the Company that it may now enroll patients at US clinical sites into two ongoing randomized, double-blind Phase II trials of its lead product, nimotuzumab. One of the two trials is in non-small-cell lung cancer (NSCLC) patients who are ineligible for curative treatment and being treated palliatively and the other in patients with brain metastases from NSCLC. Current NSCLC palliative treatment and treatment for brain metastases is radiation alone.
The Partnership to Fight Chronic Disease released a public opinion poll of Iowa health care leaders and a new study analyzing the impact of increased cost sharing on patient adherence to prescription medications. The PFCD is a nationwide coalition working to educate policy makers and the public on the costs of chronic diseases.
A study conducted by researchers at Julius-Maximilians-Universität Würzburg has shown that the antidepressant agent fluoxetine may be an effective drug for the early treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among at-risk groups.
› Verified 4 days ago
| Entity Name | North Dallas Dermatology Associates, P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629188065 PECOS PAC ID: 3173588571 Enrollment ID: O20041124000729 |
News Archive
An important new study has revealed the clearest picture yet of precisely how much measurement variation influences gene expression profiles of breast cancer.
YM BioSciences Inc., announced that the FDA has advised the Company that it may now enroll patients at US clinical sites into two ongoing randomized, double-blind Phase II trials of its lead product, nimotuzumab. One of the two trials is in non-small-cell lung cancer (NSCLC) patients who are ineligible for curative treatment and being treated palliatively and the other in patients with brain metastases from NSCLC. Current NSCLC palliative treatment and treatment for brain metastases is radiation alone.
The Partnership to Fight Chronic Disease released a public opinion poll of Iowa health care leaders and a new study analyzing the impact of increased cost sharing on patient adherence to prescription medications. The PFCD is a nationwide coalition working to educate policy makers and the public on the costs of chronic diseases.
A study conducted by researchers at Julius-Maximilians-Universität Würzburg has shown that the antidepressant agent fluoxetine may be an effective drug for the early treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among at-risk groups.
› Verified 4 days ago
| Entity Name | Dallas Dermatology Partners, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871114504 PECOS PAC ID: 8022449446 Enrollment ID: O20200518003276 |
News Archive
An important new study has revealed the clearest picture yet of precisely how much measurement variation influences gene expression profiles of breast cancer.
YM BioSciences Inc., announced that the FDA has advised the Company that it may now enroll patients at US clinical sites into two ongoing randomized, double-blind Phase II trials of its lead product, nimotuzumab. One of the two trials is in non-small-cell lung cancer (NSCLC) patients who are ineligible for curative treatment and being treated palliatively and the other in patients with brain metastases from NSCLC. Current NSCLC palliative treatment and treatment for brain metastases is radiation alone.
The Partnership to Fight Chronic Disease released a public opinion poll of Iowa health care leaders and a new study analyzing the impact of increased cost sharing on patient adherence to prescription medications. The PFCD is a nationwide coalition working to educate policy makers and the public on the costs of chronic diseases.
A study conducted by researchers at Julius-Maximilians-Universität Würzburg has shown that the antidepressant agent fluoxetine may be an effective drug for the early treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among at-risk groups.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Melissa I Costner, MD 17051 Dallas Pkwy Ste 350, Addison, TX 75001-7107 Ph: (214) 702-0029 | Melissa I Costner, MD 17051 Dallas Pkwy Ste 350, Addison, TX 75001-7107 Ph: (214) 702-0029 |
News Archive
An important new study has revealed the clearest picture yet of precisely how much measurement variation influences gene expression profiles of breast cancer.
YM BioSciences Inc., announced that the FDA has advised the Company that it may now enroll patients at US clinical sites into two ongoing randomized, double-blind Phase II trials of its lead product, nimotuzumab. One of the two trials is in non-small-cell lung cancer (NSCLC) patients who are ineligible for curative treatment and being treated palliatively and the other in patients with brain metastases from NSCLC. Current NSCLC palliative treatment and treatment for brain metastases is radiation alone.
The Partnership to Fight Chronic Disease released a public opinion poll of Iowa health care leaders and a new study analyzing the impact of increased cost sharing on patient adherence to prescription medications. The PFCD is a nationwide coalition working to educate policy makers and the public on the costs of chronic diseases.
A study conducted by researchers at Julius-Maximilians-Universität Würzburg has shown that the antidepressant agent fluoxetine may be an effective drug for the early treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among at-risk groups.
› Verified 4 days ago
Dr. Melissa Anne Rubenstein, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 17051 Dallas Pkwy Ste 350, Addison, TX 75001 Phone: 214-702-0029 Fax: 214-382-3453 | |
Sonya Sunder Jagwani, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 17051 Dallas Pkwy Ste 350, Addison, TX 75001 Phone: 314-374-3614 |